ERBB2 and gastroesophageal junction adenocarcinoma: The phase 3 KEYNOTE-811 study will evaluate the efficacy and safety of pembrolizumab in combination with trastuzumab and chemotherapy as first-line therapy in patients with advanced HER2-positive gastric or GEJ adenocarcinoma.